The journal of Clinical Medicine has published the results of phase I and II studies of the Alvac vaccine

The journal EClinicalMedicine published by The Lancet published an article presenting the results of clinical trials of the first and second phases of the domestic vaccine QazVac (QazCovid-in ® ).
According to the article, the vaccine is safe, well tolerated and contributes to the formation of pronounced humoral immunity, which persists for at least 6 months after double intramuscular immunization.
Recall that the QazVac vaccine (QazCovid-in ® ) is an inactivated vaccine against coronavirus infection COVID-19, developed by the RSE on PCV "Research Institute of Biological Safety Problems" of the Committee of Science of the Ministry of Education and Science of the Republic of Kazakhstan.
The vaccine was issued a temporary registration certificate in accordance with the Rules of temporary state registration of vaccines against the Covid-19 coronavirus produced in the Republic of Kazakhstan, approved by the Decree of the Government of the Republic of Kazakhstan dated December 15, 2020 No. 850.

You can read the full text of the study at the link:
https://www.sciencedirect.com/science/article/pii/S2589537021003588?fbclid=IwAR0ftOesF9Fv03TjziYu_MmkALkRhNRYL4sJQEAJQwVtR54NTEpVnvY8SBw